Home › Research › Treatments
Anti‐amyloid antibodies in Europe: Where are we now?
Danica Juričić Nahal, Petar Mas, Ivana Cegec, Margareta Bego, Iva Klarica Domjanović. British Journal of Clinical Pharmacology, 2026-03-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
In the pivotal study in the overall population, the treatment showed a difference of −0.45 points between lecanemab and placebo in the adjusted mean change from baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months (the primary endpoint). Safety concerns focused on amyloid-related imaging abnormalities (ARIA) as potentially fatal adverse events, with ARIA manifesting as oedema or effusion (ARIA-E) occurring in 12.6% of lecanemab-treated patients (vs. 1.7% on placebo) and ARIA manifesting as microhaemorrhages and hemosiderin deposits (ARIA-H) in 16.9% (vs. 8.9% on placebo) in the overall population. Furthermore, additional data from the TRAILBLAZER-ALZ 6 trial demonstrated that a gradual titration scheme further reduced ARIA-E incidence at 24 weeks while maintaining efficacy.2 Views regarding the approval varied greatly. While some Alzheimer experts viewed the results as clinically relevant,3 others were critical of the approval and the RMMs imposed.4 As anti-amyloid antibodies transition from the rigours of regulatory assessment into clinical practice, the pivotal question evolves from efficacy to implementation. However, the practical implementation of RMMs present significant logistical challenges that vary by clinical setting.
What this study adds
Evidence grade: Moderate
This is a trial. In the pivotal study, lecanemab differed from placebo by −0.45 points on the CDR-SB at 18 months, and ARIA occurred more often in treated patients, including ARIA-E in 12.6% versus 1.7% on placebo. Reported effect size: 12.6%; 1.7%; 16.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nahal, D. J., Mas, P., Cegec, I., Bego, M., & Domjanović, I. K. (2026). Anti‐amyloid antibodies in Europe: Where are we now? British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70526
Vancouver
Nahal DJ, Mas P, Cegec I, Bego M, Domjanović IK. Anti‐amyloid antibodies in Europe: Where are we now? British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70526. PMID: 41810890.
BibTeX
@article{nahal2026-41810890,
author = {Nahal, Danica Juričić and Mas, Petar and Cegec, Ivana and Bego, Margareta and Domjanović, Iva Klarica},
title = {{Anti‐amyloid antibodies in Europe: Where are we now?}},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70526},
pmid = {41810890},
url = {https://doi.org/10.1002/bcp.70526}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In the pivotal study in the overall population, the treatment showed a difference of −0.45 points between lecanemab and placebo in the adjusted mean change from baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months (the primary endpoint).
- Safety concerns focused on amyloid-related imaging abnormalities (ARIA) as potentially fatal adverse events, with ARIA manifesting as oedema or effusion (ARIA-E) occurring in 12.6% of lecanemab-treated patients (vs. 1.7% on placebo) and ARIA manifesting as microhaemorrhages and hemosiderin deposits (ARIA-H) in 16.9% (vs. 8.9% on placebo) in the overall population.
- Furthermore, additional data from the TRAILBLAZER-ALZ 6 trial demonstrated that a gradual titration scheme further reduced ARIA-E incidence at 24 weeks while maintaining efficacy.2 Views regarding the approval varied greatly.
- While some Alzheimer experts viewed the results as clinically relevant,3 others were critical of the approval and the RMMs imposed.4 As anti-amyloid antibodies transition from the rigours of regulatory assessment into clinical practice, the pivotal question evolves from efficacy to implementation.
- However, the practical implementation of RMMs present significant logistical challenges that vary by clinical setting.
Why it matters
In the pivotal study, lecanemab differed from placebo by −0.45 points on the CDR-SB at 18 months, and ARIA occurred more often in treated patients, including ARIA-E in 12.6% versus 1.7% on placebo. As these antibodies move into practice, the main question shifts from efficacy to how to implement the required risk management measures, which pose logistical challenges that vary by clinical setting.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Effect size12.6%; 1.7%; 16.9%
- Evidence strengthModerate
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (British Journal of Clinical Pharmacology) |
| Journal's citation record | 2 / 4 | British Journal of Clinical Pharmacology: journal h-index 221 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Iva Klarica Domjanović: h-index 5 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University Hospital Centre Zagreb: institution h-index 259 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41810890) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.